More recent agents include dual agonists such as tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and produces even greater weight loss
Get started In clinical trials of the oral Wegovy (semaglutide) pill, participants taking the medication with diet and exercise achieved average weight loss of about 14%17% over ~64 weeks compared with ~2% with placebo
Interventions included semaglutide, liraglutide, tirzepatide, and exenatide, with treatment durations ranging from 40 to 120 weeks
Will semaglutide alone give me the same weight loss as phentermine plus Wegovy
Demonstrated positive response defined as 5% reduction from baseline body weight (adults) or baseline BMI (pediatrics), or maintenance of weight loss with continued participation in a weight management program that includes lifestyle modification, exercise, and reduced calorie diet
Stay informed on FDA enforcement, private litigation, and telehealth risks impacting compounded GLP-1s and peptides
